The GLP-1/GIP dual-receptor agonist tirzepatide led to at least 15% loss of total body fat in premenopausal, perimenopausal, and postmenopausal women, but postmenopausal women taking menopausal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback